Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Find the latest HCM Defender 100 Index ETF (QQH) stock quote, history, news and other vital information to help you with your stock trading and investing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results